Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3526806 | 0.86 | GRM2 (0.37) | HSD11B1CYP3A4P2RX7L3MBTL1TDP1 | |
| SCHEMBL3526700 | 0.86 | KDM4E (0.39) | HSD11B1CYP3A4P2RX7L3MBTL1TDP1 | |
| SCHEMBL3533292 | 0.83 | HSD11B1 (0.46) | HSD11B1CYP3A4APLNRL3MBTL1TDP1 | |
| SCHEMBL3532454 | 0.82 | ALDH1A1 (0.38) | HSD11B1APLNRP2RX7TDP1MEN1 | |
| SCHEMBL3529340 | 0.79 | HSD11B1 (0.45) | HSD11B1CYP3A4APLNRL3MBTL1TDP1 | |
| SCHEMBL3527170 | 0.77 | HSD11B1 (0.46) | HSD11B1CYP3A4P2RX7L3MBTL1TDP1 | |
| SCHEMBL3526545 | 0.77 | CYP3A4 (0.41) | HSD11B1CYP3A4P2RX7L3MBTL1TDP1 | |
| SCHEMBL3533087 | 0.72 | MCHR1 (0.33) | HSD11B1P2RX7 | |
| SCHEMBL3533392 | 0.72 | GRM2 (0.38) | HSD11B1L3MBTL1TDP1MEN1KMT2A | |
| SCHEMBL3525634 | 0.72 | HSD11B1 (0.43) | HSD11B1CYP3A4APLNRP2RX7L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652057-B2 | Pyrazolones as 11b-HSD1 inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2010-01-26 | — | — | US | disclosed |
| EP-1924562-A2 | PYRAZOLONE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007025880-A2 | PYRAZOLONE DERIVATIVES AS 11-BETA HSD1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | F. HOFFMANN-LA ROCHE AG (CH) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049574-A1 | New pyrazolones as 11b-HSD1 inhibitors for diabetes | HSD11B1, HSD17B1, HSD17B7 | HSD11B1 1/4885CYP3A4 45/4885APLNR 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.